Lehrstuhl für Innere Medizin IV

Blood pressure reduction in higher cardiovascular risk patients in the Global SYMPLICITY Registry (2022) Rodriguez O, Mahfoud F, Schmieder R, Schlaich M, Narkiewicz K, Ruilope L, Williams B, et al. Journal article PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease (2022) Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Pietschner R, Ott C, Schiffer M, et al. Conference contribution Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial (2022) Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, et al. Journal article Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial (2022) Bloch M, Kirtane A, Mahfoud F, Azizi M, Basile J, Daemen J, Saxena M, et al. Conference contribution Influence of Gender on Blood Pressure Reduction After Renal Denervation in GSR DEFINE (2022) Weil J, Mahfoud F, Schmieder R, Narkiewicz K, Williams B, Fahy M, Mancia G Conference contribution Prevalence of hereditary tubulointerstitial kidney diseases in the German Chronic Kidney Disease study (2022) Popp B, Ekici AB, Knaup K, Schneider K, Uebe S, Park J, Bafna V, et al. Journal article Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry (2022) Schmieder R, Mahfoud F, Mancia G, Narkiewicz K, Ruilope L, Hutton D, Cao K, et al. Journal article Treatment effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people underrepresented from the ontarget trial: Analysis of routinely collected data using trial replication methods (2022) Baptiste PJ, Wong A, Schultze A, Cunnington M, Mann J, Clase C, Leyrat C, et al. Conference contribution Detecting tandem repeat variants in coding regions using code-adVNTR (2022) Park J, Bakhtiari M, Popp B, Wiesener M, Bafna V Journal article An intermediate-effect size variant in UMOD confers risk for chronic kidney disease (2022) Olinger E, Schaeffer C, Kidd K, Elhassan EA, Cheng Y, Dufour I, Schiano G, et al. Journal article